CRSP · CRISPR Therapeutics AG · Executive Compensation
$58.49
+1.15 (+2.01%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$5.45B
Shares
96.69M
Volume · Oct 5
1.7M
Avg daily vol (3M)
1.58M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Julianne Bruno | Chief Operating Officer | Resigned | 2025-03-26 |
| Christian Rommel, Ph.D. | member of the Company's Board of Directors | Appointed | 2024-06-03 |
| Sandesh Mahatme, LL.M. | member of the Company's Board of Directors | Appointed | 2024-06-03 |
| Julianne Bruno | Chief Operating Officer | Appointed | 2024-05-23 |
| Phuong Khanh Morrow, M.D., FACP | Chief Medical Officer | Resigned | 2023-12-19 |
| Samarth Kulkarni, Ph.D. | Chairman of the Board | Appointed | 2023-09-07 |
| Rodger Novak, M.D. | director | Resigned | 2023-09-07 |
| Rodger Novak, M.D. | President of the Company | Resigned | 2023-09-07 |
| Rodger Novak, M.D. | Chairman of the Company's Board of Directors | Resigned | 2023-09-07 |
| Bradley Bolzon | director | Resigned | 2023-03-29 |
| Brendan Smith | Executive Vice President and Chief Financial Officer | Resigned | 2023-03-14 |
| Raju Prasad, Ph.D. | Chief Financial Officer | Appointed | 2023-03-14 |
| Lawrence O. Klein | Chief Operating Officer | Resigned | 2022-10-27 |
Key facts
CIK
1674416
CUSIP
H17182108
13F (30d)
14 filings
10 filers
Visit website
Investor relations